台灣臨床試驗主持人資料庫|TPIDB

2018-04-01 - 2019-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Conventional Therapies but Have Not Failed Biologic Therapy

Condition/Disease

Moderately to Severely Active Crohn's Disease
Test Drug

Upadacitinib (ABT-494)

Participate Sites
4Sites

Recruiting3Sites

周仁偉

China Medical University Hospital-Taipei

未分科

2016-10-10 - 2022-08-31

Phase III

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ABT-494 for induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis.

Condition/Disease

Ulcerative colitis
Test Drug

Upadacitinib(ABT-494)

Participate Sites
8Sites

Terminated6Sites

周仁偉

China Medical University Hospital-Taipei

未分科

林春吉

Taipei Veterans General Hospital

Division of Colorectal Surgery

2017-12-01 - 2020-04-01

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

Condition/Disease

Crohn’s Disease
Test Drug

Risankizumab(ABBV-066)

Participate Sites
6Sites

Terminated5Sites

周仁偉

China Medical University Hospital-Taipei

未分科

2016-06-06 - 2022-03-10

Phase III

A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs

Condition/Disease

Rheumatoid Arthritis
Test Drug

ABT-494

Participate Sites
8Sites

Terminated7Sites

黃春明

China Medical University Hospital-Taipei

未分科

2017-04-01 - 2018-12-31

Phase III

A Single Arm, Open-label Study to Evaluatehe Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naive Adults with Chronic Hepatitis C Virus (HCV) Genotype 1, 2,4, 5 or 6Infection and Compensated Cirrhosis

Condition/Disease

Chronic Hepatitis C Virus (HCV)
Test Drug

Glecaprevir、Pibrentasvir

Participate Sites
4Sites

Terminated3Sites

彭成元

China Medical University Hospital-Taipei

未分科

朱啟仁

Taipei Veterans General Hospital

Digestive System Department

2018-11-01 - 2021-03-30

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis

Condition/Disease

Moderately to Severely Active Ulcerative Colitis
Test Drug

Upadacitinib (ABT-494)

Participate Sites
6Sites

Recruiting2Sites

Terminated2Sites

周仁偉

China Medical University Hospital-Taipei

未分科

林春吉

Taipei Veterans General Hospital

Division of Colorectal Surgery

2018-08-31 - 2020-12-31

Phase II

Efficacy and safety of 3 doses of S201086/GLPG1972 administered orally once daily in patients with kneeosteoarthritis. A 52-week international, multi-regional, multicenter,randomized, double-blind, placebo-controlled, doseranging study.

Condition/Disease

kneeosteoarthritis
Test Drug

S201086/GLPG1972

Participate Sites
4Sites

Terminated3Sites

黃春明

China Medical University Hospital-Taipei

未分科

2018-11-01 - 2021-12-31

Phase III

A Randomized, Controlled, Double-blind Continuation Study Comparing the Long-term Safety and Efficacy of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Subjects with Lupus Nephritis

Condition/Disease

Lupus Nephritis
Test Drug

Orelvo (voclosporin)

Participate Sites
4Sites

Terminated2Sites

藍忠亮

China Medical University Hospital-Taipei

未分科

藍忠亮

China Medical University Hospital

Division of Rheumatology

2017-04-01 - 2019-07-31

Phase III

A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Nephritis

Condition/Disease

Active Lupus Nephritis
Test Drug

Orelvo (voclosporin)

Participate Sites
5Sites

Terminated3Sites

Study ended1Sites

藍忠亮

China Medical University Hospital-Taipei

未分科

藍忠亮

China Medical University Hospital

Division of Rheumatology

2017-08-10 - 2021-06-30

Phase III

A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma

Condition/Disease

Esophageal Squamous Cell Carcinoma
Test Drug

Nivolumab/Ipilimumab

Participate Sites
15Sites

Terminated13Sites

林振源

China Medical University Hospital-Taipei

未分科

陳明晃

Taipei Veterans General Hospital

Division of Hematology & Oncology

Search Result

List